---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Intravesical drug-releasing systems"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Intravesical drug-releasing systems. Topics: FDA-approved indication and mechanism: gemcitabine intravesical system, European guideline description of TAR-200, Dosage and administration, SunRISe-1 Cohort 2: design and population, and 6 further topics. 10 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/intravesical-drug-releasing-systems"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Intravesical drug-releasing systems

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Intravesical Drug-releasing Systems

<a id="topic-2.2.2.1.5-1"></a>

### FDA-approved indication and mechanism: gemcitabine intravesical system

> “INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.”
> “INLEXZO is a nucleoside metabolic inhibitor-containing intravesical system”
> “Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

### European guideline description of TAR-200

> “TAR-200 is an intravesical system for the continuous release of gemcitabine, providing a sustained dose to increase the therapeutic window of intravesical exposure and enhance targeted treatment within the bladder.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### Dosage and administration

> “Insert INLEXZO (225 mg of gemcitabine) into the bladder once every 3 weeks for up to 6 months (8 doses), followed by once every 12 weeks for up to 18 months (6 doses), or until persistent or recurrent NMIBC, disease progression, or unacceptable toxicity.”
> “Remove INLEXZO after each 3-week indwelling period.”
> “INLEXZO is co-packaged with a urinary catheter and stylet used to insert INLEXZO through the urinary catheter into the bladder.”
> “INLEXZO is a hazardous drug.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

### SunRISe-1 Cohort 2: design and population

> “The efficacy of INLEXZO was evaluated in Cohort 2 of SunRISe-1 (NCT04640623), a single-arm, multi-center trial in 83 adults with BCG-unresponsive, NMIBC with CIS, with or without papillary tumors (T1, or high-grade Ta) following transurethral resection.”
> “The trial included patients who were ineligible for or who had elected not to undergo radical cystectomy and excluded patients with extra-vesical (i.e., urethra, ureter, or renal pelvis), muscle invasive (T2-T4), locally advanced, or metastatic urothelial carcinoma.”
> “Mandatory biopsies were performed 24 and 48 weeks after treatment initiation.”
> “The major efficacy outcome measures were complete response rate at any time”
> “Tumor pattern at study entry was CIS only (67%), CIS with high-grade Ta only (22%), and CIS with T1 (11%).”
> “The median number of prior instillations of BCG was 12 (range: 7 to 42).”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

### SunRISe-1 Cohort 2: efficacy in the prescribing information

| Endpoint | Gemcitabine intravesical system |
| --- | --- |
| Participants | “N=83” |
| Complete response rate (95% CI) | “82% (72, 90)” |
| Duration of response, range in months | “0+, 44+” |
| Duration of response ≥12 months, % (n) | “51% (35)” |
| Basis of duration of response | “Based on patients (n=68) with a complete response at any time” |

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

### SunRISe-1 Cohort 2: published complete response and duration of response

> “The centrally confirmed CR rate in Cohort 2 was 82.4% (95% CI, 72.6 to 89.8), with 70 of 85 patients achieving CR”
> “After a median follow-up in responders of 20.2 months (range, 5-48), median DOR was 25.8 months (95% CI, 8.3 to not estimable”
> “Among 70 responders, 37 (52.9%) had a DOR of ≥12 months.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.2.2.1.5-7"></a>

### SunRISe-1 Cohort 4: papillary-only disease

> “Fifty-two patients with BCG-unresponsive high-risk papillary disease–only NMIBC received TAR-200 monotherapy”
> “The Cohort 4 primary end point was disease-free survival (DFS).”
> “After a median follow-up of 12.8 months (range, 4-17), the median DFS was not estimable.”
> “At 6, 9, and 12 months, DFS rates were 85.3% (95% CI, 71.6 to 92.7), 81.1% (95% CI, 66.7 to 89.7), and 70.2 (95% CI, 51.6 to 82.8), respectively”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-2.2.2.1.5-8"></a>

### Safety in SunRISe-1 Cohort 2

> “Serious adverse reactions occurred in 24% of patients receiving INLEXZO.”
> “Fatal adverse reactions occurred in 1.2% of patients who received INLEXZO, including cognitive disorder.”
> “Permanent discontinuation of INLEXZO due to an adverse reaction occurred in 7% of patients.”
> “Dosage interruptions of INLEXZO due to an adverse reaction occurred in 41% of patients.”
> “The most common (>15%) adverse reactions, including laboratory abnormalities, were urinary frequency, urinary tract infection, dysuria, micturition urgency, decreased hemoglobin, increased lipase, urinary tract pain, decreased lymphocytes, hematuria, increased creatinine, increased potassium, increased AST, decreased sodium, bladder irritation, and increased ALT.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-9"></a>

### Progression to muscle-invasive disease and MRI conditions

> “Of the 83 evaluable patients with BCG-unresponsive CIS treated with INLEXZO in Cohort 2 of SunRISe-1, seven patients (8%) progressed to muscle invasive (T2 or greater) bladder cancer.”
> “The median time between determination of persistent or recurrent CIS or T1 and progression to muscle invasive disease was 94 days.”
> “INLEXZO may be used with MRI only under the specific predefined conditions provided below to avoid potential safety hazards or severe adverse reactions.”

Source: [Inlexzo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219683s000lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

### Randomized phase 3 trial in papillary-only disease: SunRISe-5

> “The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of”
> “who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.”

Source: [ClinicalTrials.gov NCT06211764](https://clinicaltrials.gov/study/NCT06211764)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
